(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of nanoparticle technology - Announces partnership with Glasgow-based University of Strathclyde's CMAC National Facility, aimed at accelerating development and broadening therapeutic applications. The collaboration combines N4 Pharma's Nuvec delivery platform with CMAc's expertise. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Monday. Read More
(Alliance News) - N4 Pharma PLC on Monday said its Nuvec gene delivery system has successfully demonstrated targeted delivery of RNA to lung cancer cells in collaboration with US research institute SRI. Read More
(Alliance News) - London stocks were mixed at Monday's market open, with miners dominating the top spots on the FTSE 100 index while airlines were hurt after the weekend's alleged cyber attack. Read More
(Alliance News) - N4 Pharma PLC shares jumped on Monday as it reported positive results from the first in vivo study of its proprietary gene delivery system Nuvec for inflammatory bowel disease. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Wednesday. Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of nanoparticle technology Nuvec - Notes SRI International has successfully completed the chemistry work and shown that a fox three molecular guidance system can be added to Nuvec without altering its loading capability. Chief Executive Nigel Theobald says: "This is an exciting development for us as it clearly shows that Nuvec is capable of targeting specific cells via the addition of a relevant ligand, something the industry is actively looking for. We will now start working on a combined marketing pitch deck allowing SRI and N4 Pharma to present this data and its implications to major pharma and biotech players that need a targeting delivery system for their nucleic acid programs." N4 Pharma says the next step is to show that small interfering RNA still retains its functionality in the target cell. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - N4 Pharma PLC on Friday said it has raised GBP630,000 through a placing and subscription of shares. Read More
(Alliance News) - N4 Pharma PLC on Thursday said it has entered into a collaboration agreement with SRI International Inc. Read More
N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of Nuvec - Posts revenue of GBP1,953 in 2023, compared to no revenue a year ago. Pretax loss widens to GBP1.4 million from GBP1.2 million. Looks ahead to the rest of 2024 with "great optimism." Read More
(Alliance News) - N4 Pharma PLC on Thursday reported that its novel delivery system for cancer treatment has shown promise, after a successful trial. Read More
N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - Reports an "encouraging" update from its Nuvec delivery system for cancer treatments, gene therapy and vaccines. It has completed in-vitro experiments combining epidermal growth factor receptor and polo like kinase 1 molecules onto a Nuvec nanoparticle, before testing it on lung cancer cells. "The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle," N4 says. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More